ZoomInfo logo

ZoomInfo

ZoomInfo is a software company that provides a go-to-market intelligence and sales/marketing platform using AI and data to help...

Facts

HQ
NASDAQ
Sectors
Software Development
Employees
7527
Stage
Public
Total raised
$2.6M SEC Form D filings Total of this company's SEC Form D filings
Last round
$775.9K · Apr 2025 SEC Form D
Founders
Henry Schuck

Clarify acquires Seam AI to power Clarify Signals, adds five employees including Seam CEO Nicholas Scavone

Seattle AI startup Clarify, which has raised $22.5 million, acquired San Francisco-based Seam AI to integrate its proprietary web monitoring signals into a new product, Clarify Signals, launching later this year; five Seam employees including CEO Nicholas Scavone will join Clarify. Financial terms were not disclosed, though Clarify said it raised additional undisclosed funding as part of the deal.

Vieu launches Business Graph, an AI-ready map of business relationships after $11M seed; serves 100+ enterprise customers

Seattle startup Vieu launched the Business Graph, a live map of business relationships built from observed signals (shared work history, board affiliations, co-authorships) to help B2B sales, recruiting, marketing and fundraising. The 40-person company raised an $11M seed in October 2024, serves over 100 enterprise customers, integrates with CRMs and AI assistants, and charges a platform fee plus outcome-based pricing.

Levanta Achieves Over 10X ROI and Millions in Contracts Using ZoomInfo's AI GTM Platform by Targeting High-Growth Brands

Levanta, an affiliate marketing platform connecting e-commerce sellers with creators, achieved over 10X ROI using ZoomInfo's AI GTM platform and closed millions in contracts by targeting high-growth brands with precise data. Their targeted approach involved leveraging ZoomInfo filters and buying signals to effectively reach decision-makers and scale revenue.

UW Genetics Professor Mary-Claire King Awarded NAS Public Welfare Medal; T-Mobile Board and Seattle Startup Violett Announce Leadership Changes

Mary-Claire King, a University of Washington genetics professor, received the National Academy of Sciences' Public Welfare Medal for her impactful genome science work including discovering the BRCA1 gene. T-Mobile announced board changes with the return of Thomas Dannenfeldt and resignations of Kelvin Westbrook and Srinivasan Gopalan, while Seattle startup Violett appointed Michael Kurtzman as CEO.

Deloitte’s 2021 Fast 500 Includes 26 Washington Firms; Coinme Tops Seattle Growth at 2,198% (Rank 78)

Deloitte’s 2021 North American Technology Fast 500 ranks the fastest-growing tech companies by revenue growth from 2017–2020; 26 Washington-based firms made the list, with 24 from the greater Seattle area and strong representation from Bellevue and software/SaaS companies. Coinme led local growth with 2,198% growth (ranked 78th), and Washington firms comprised about 5% of the full Fast 500.

Absci opens 77,400 sq ft HQ in Vancouver, Wash., three months after IPO valued company near $2 billion

Absci opened a 77,400 sq ft headquarters with a 9,150 sq ft courtyard in Vancouver, Wash., three months after its IPO that valued the company at nearly $2 billion; Gov. Jay Inslee attended the ribbon-cutting. The 200-employee biotech — founded in 2011 by CEO Sean McClain — provides drug discovery services using in silico models, synthetic biology and recent acquisitions Totient and Denovium to support its platform.

Relevvo raises $1.5M seed to power personalized B2B sales messaging from Microsoft and LinkedIn veterans

Seattle startup Relevvo, founded by veterans from Microsoft, LinkedIn and other firms, raised a $1.5 million seed round to sell a B2B ‘relevance engine’ that delivers personalized sales messaging at scale to replace ‘spray and pray’ outreach. The seven-person company counts customers like iSpot, Esper, Hiya and CourseKey and was founded by Aashish Dhamdhere and Tushar Shanbhag.

Sana Biotechnology Raises $587.5M in IPO, Debuts on Nasdaq as SANA with $6B Market Value

Sana Biotechnology raised $587.5 million by pricing 23.5 million shares at $25 in its IPO and began trading on Nasdaq under ticker SANA, with shares jumping about 40% on debut to close at $35.10. The 3-year-old Seattle gene-editing company, pre-revenue and led by former Juno executives, aims to use the proceeds to advance gene and cell therapies—including cancer treatments—and may file drug applications as early as 2022.

Accolade files IPO to sell 8.75M shares at $19–$21, seeks up to $211M and ~$1B valuation; will trade as ACCD

Accolade priced 8.75 million IPO shares at $19–$21 to raise up to $211 million, aiming for a ~ $1 billion valuation and Nasdaq ticker ACCD, positioning itself as Seattle's first public company of 2020. The health benefits platform reported $132.5 million revenue and a $51.3 million net loss for the fiscal year ending Feb. 29, serves 1.6 million members across 58 corporate customers, and estimates a $24 billion total addressable market.

People

Online